课题基金 / 基金详情

A Spontaneous Mouse Model of Motor Neuron Disease

A Spontaneous Mouse Model of Motor Neuron Disease
运动神经元疾病的自发小鼠模型
批准号:
8130983
负责人:
Robert W Burgess
金额:
$26.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2013-08-31

项目摘要

项目成果

Robert W Burgess的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本提案的目标是描述一种新的运动神经元病的自发小鼠模型,并鉴定致病突变。运动神经元疾病,如肌萎缩侧索硬化症(ALS)和脊髓肌萎缩症(SMA)在人群中很常见,对患者的严重程度是毁灭性的。尽管在动物模型和人类中都发现了一些与可遗传运动神经元疾病相关的基因,但这些疾病的分子基础仍然不清楚。这些疾病的动物模型对于研究致病机制、为寻找治疗靶点提供信息以及为测试疗法提供临床前模型是至关重要的。许多现有的运动神经元疾病的动物模型都经过了大量的工程设计,以准确复制人类疾病的遗传学为代价来复制疾病的表型。例如,人类SOD1的显性突变导致家族性肌萎缩侧索硬化症,而小鼠模型需要过度表达突变形式的人类蛋白质才能发展出类似的表型。相比之下,由于相关表型而在小鼠身上识别出的自发突变根本不是工程设计的,因此避免了转基因模型的许多警告。例如,考克斯博士发现的Ighmbp2基因的自发突变会导致小鼠的一种运动神经元疾病,这直接导致了人类脊髓肌萎缩伴呼吸窘迫的遗传基础的确定。最近,我们在小鼠身上发现了一种新的自发隐性突变,导致运动神经元病的表型。这种模型表现出明显的、进行性的神经肌肉功能丧失,特别是在后肢,在5-6个月大时几乎完全瘫痪。检查脊神经根和神经肌肉接头显示运动神经元缺陷,检查脊髓腹角运动神经元胞体显示病理,包括富含伊红的泛素阳性包涵体。这个模型的病理和表型不同于之前描述的小鼠模型,但准确地概括了人类运动神经元疾病的许多特征。因此,我们提出了两个目标来研究这种新的运动神经元病模型。在目标1中,我们将通过综合分析大体运动表现、电生理特征、组织学、免疫细胞化学和电子显微镜来检测表型,以了解运动神经元的疾病进展和病理。这些信息将使我们能够准确地将小鼠的表型与相关的人类疾病联系起来。在目标2中,我们将使用位置克隆技术来鉴定致病突变。识别潜在的遗传缺陷对于了解运动神经元丢失的基础至关重要。如果这种突变发生在已知的运动神经元病基因中,它很可能代表了相关人类疾病的更好的动物模型。如果突变是在一个新的基因中,它将为导致运动神经元病的分子途径提供额外的机械性见解,并为相关人类疾病提供一个新的候选基因。 公共卫生相关性:运动神经元疾病,如肌萎缩侧索硬化症和脊髓肌萎缩症,其严重性是毁灭性的,但其潜在的病理机制尚不清楚,目前的治疗方法效果有限。我们已经确定了一种新的、可遗传的运动神经元病小鼠模型,并提议克隆相关基因。这项工作将增加我们对运动神经元疾病的了解,从而有助于寻找治疗靶点。此外,它将为现有的人类疾病提供一个更好的动物模型,或者更有可能为患者的家族性运动神经元疾病识别新的候选基因。
英文摘要
DESCRIPTION (provided by applicant): The goal of this proposal is to characterize a new spontaneous mouse model of motor neuron disease and identify the causative mutation. Motor neuron diseases such as Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophies (SMA) are common in the population and devastating in their severity for the patient. The molecular basis for these diseases is still unclear despite the identification of a handful of genes associated with heritable motor neuron diseases in both animal models and humans. Animal models of these diseases are critical for research on the pathogenic mechanisms to inform the search for therapeutic targets and to provide preclinical models for testing therapies. Many existing animal models of motor neuron diseases are heavily engineered to reproduce the disease phenotype at the expense of accurately reproducing the genetics of the human disease. For example, dominant mutations in SOD1 in humans cause a familial form of ALS, whereas mouse models require overexpression of mutant forms of the human protein to develop a similar phenotype. In contrast, spontaneous mutations in mice identified because of their related phenotypes are not engineered at all and therefore avoid many caveats of transgenic models. For example, spontaneous mouse mutations in Ighmbp2 identified by Dr. Cox, a PI on this proposal, cause a motor neuron disease in mice that directly led to the identification of the genetic basis of Spinal Muscular Atrophy with Respiratory Distress in humans. Recently, we have identified a novel spontaneous recessive mutation in mice that causes a motor neuron disease phenotype. This model displays overt, progressive loss of neuromuscular function, particularly in the hind limbs, with almost complete paralysis by 5-6 months of age. Examination of spinal roots and neuromuscular junctions indicate a motor neuron defect, and examination of motor neuron cell bodies in the spinal cord ventral horn reveals pathology including eosin-rich, ubiquitin-positive inclusions. The pathology and phenotype of this model differ from previously described mouse models, but accurately recapitulates many of the hallmarks of human motor neuron diseases. We therefore propose two aims to study this new model of motor neuron disease. In Aim 1, we will examine the phenotype using an integrated analysis of gross motor performance, electrophysiological characterization, and histology, immunocytochemistry, and electron microscopy to understand the disease progression and pathology in the motor neurons. This information will allow us to accurately correlate the mouse phenotype with related human diseases. In Aim 2, we will use positional cloning techniques to identify the causative mutation. Identifying the underlying genetic defect is critical for understanding the basis of the motor neuron loss. If this mutation is in a known motor neuron disease gene, it is likely to represent a superior animal model of the associated human disease. If the mutation is in a novel gene, it will provide additional mechanistic insights into the molecular pathways that lead to motor neuron disease and also provide a new candidate gene for related human diseases. PUBLIC HEALTH RELEVANCE: Motor neuron diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy are devastating in their severity, but the underlying pathological mechanisms are poorly understood and current therapies are of limited effectiveness. We have identified a new, heritable mouse model of motor neuron disease and propose to clone the gene responsible. This work will add to our understanding of motor neuron diseases, and therefore aid the search for therapeutic targets. In addition, it will either provide a superior animal model for an existing human disease, or more likely, identify a new candidate gene for familial motor neuron diseases in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dissecting the Integrated Stress Response in tRNA Synthetase-Associated Neuropathies
  • 批准号:
    10647281
  • 项目类别:
  • 资助金额:
    $21.64万
  • 财政年份:
    2023
  • 负责人:
    Robert W Burgess
  • 依托单位:
Testing SARM1 as a Therapeutic Target in Multiple Forms of Charcot-Marie-Tooth Disease
  • 批准号:
    10526224
  • 项目类别:
  • 资助金额:
    $17.31万
  • 财政年份:
    2022
  • 负责人:
    Robert W Burgess
  • 依托单位:
The Genetics of the Neuromuscular Junction: Mechanisms and Disease Models
  • 批准号:
    10303668
  • 项目类别:
  • 资助金额:
    $27.78万
  • 财政年份:
    2021
  • 负责人:
    Robert W Burgess
  • 依托单位:
Exploring the Functions of tRNA Synthetases in the Nucleus and their Relationship to CMT
  • 批准号:
    10588027
  • 项目类别:
  • 资助金额:
    $3.07万
  • 财政年份:
    2020
  • 负责人:
    Robert W Burgess
  • 依托单位:
海外基金